Topical Ruxolitinib in Chronic Hand Dermatitis

Topical Ruxolitinib (Jak1/Jak2 Inhibitor) in Chronic Hand Dermatitis Attenuates Inflammation and Enhances Skin Barrier Repair

NCT05293717•University of Rochester

View on ClinicalTrials.gov

Summary

This is an investigator-initiated, proof of concept, open study to assess efficacy of a topical Ruxolitinib in subjects with Chronic Hand Dermatitis (CHD). The study will be conducted at the University of Rochester Medical center, Dermatology Department - Rochester, NY. Qualified and enrolled subjects (see Inclusion/Exclusion criteria) will be required to come to URMC Dermatology Clinic for at least five visits.

Detailed Description

This is a single-center study anticipating to enroll 15 participants with chronic hand dermatitis. Eligible participants will receive Ruxolitinib to apply twice daily for 12 weeks. Participants will be required to be seen every 4 weeks until week 16.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosis of chronic hand eczema defined as hand eczema, which has persisted for more than 3 months or returned twice or more within the last 12 months.
•Disease severity graded as moderate to severe according to IGA (i.e., IGA ≥2).
•Recent history (within 1 year before the screening visit) of inadequate response to topical corticosteroid and/or calcineurin inhibitors treatment or topical corticosteroid treatment being medically inadvisable.

Exclusion Criteria

•Active atopic dermatitis in regions other than the hands requiring medical treatment.
•Active psoriasis in regions other than the hands requiring medical treatment.
•Clinically significant infection (e.g., impetiginized hand eczema or tinea manum) on the hands.
•Patients with excessive contact of hands with water (longer than 2 hours at day; or \> 20 hands washing at day) that is believed to be a predominant cause of the hand dermatitis.
•Subjects with known antigen sensitization based on Patch test (with 3 years) that are unable to reduce contact with the specific antigen(s).
•Subjects chronically and consistently exposed to known-irritant or other substance known to impact skin barrier will be excluded based on PI judgement
•Systemic treatment with immunosuppressive drugs, immunomodulating drugs, retinoids, or corticosteroids within 4 weeks prior to baseline.
•Systemic treatment with antibiotics within 4 weeks prior to baseline
•Phototherapy on the hands within 4 weeks prior to baseline.
•Use of topical immunomodulators (e.g., phosphodiesterase-4 (PDE-4) inhibitors, pimecrolimus, tacrolimus) or topical corticosteroids on the hands within 2 weeks prior to baseline.
+12 more criteria

Locations (1)

UR Medicine Dermatology College Town

Rochester, New York, United States

Key Dates

Start Date

July 11, 2022

Primary Completion Date

June 21, 2023

Completion Date

December 31, 2024

Last Updated

February 25, 2025

Enrollment

ACTUAL participants

Conditions

Chronic Hand Dermatitis

Interventions

Ruxolitinib

DRUG

Chronic Hand Eczema - Self-management and Prognosis

NCT01482663

Chronic Hand EczemaChronic Hand Dermatitis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 25, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions